Krystal Biotech (KRYS) Receivables (2023 - 2026)

Krystal Biotech (KRYS) has 4 years of Receivables data on file, last reported at $127.0 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 22.96% year-over-year to $127.0 million; the trailing twelve-month figure through Mar 2026 stood at $127.0 million (up 22.96% YoY), and the FY2025 full-year result was $127.4 million, up 21.63% from the prior year.
• Receivables held at $127.0 million in Q1 2026, from $127.4 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $129.6 million in Q3 2025 to a low of $9.3 million in Q3 2023.
• A 4-year average of $96.4 million and a median of $104.7 million in 2024 frame the typical range for Receivables.
• Across the five-year window, Receivables soared 944.42% in 2024 and fell 1.38% in 2025, its largest moves.
• Tracing KRYS's Receivables over 4 years: stood at $42.0 million in 2023, then soared by 149.16% to $104.7 million in 2024, then rose by 21.63% to $127.4 million in 2025, then fell by 0.3% to $127.0 million in 2026.
• Business Quant data shows KRYS's Receivables at $127.0 million in Q1 2026, $127.4 million in Q4 2025, and $129.6 million in Q3 2025.